Literature DB >> 20571079

The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells.

Lauren T May1, Tim J Self, Stephen J Briddon, Stephen J Hill.   

Abstract

Allosteric binding sites on adenosine -A(1) and -A(3) receptors represent attractive therapeutic targets for amplifying, in a spatially and temporally selective manner, the tissue protective actions of endogenous adenosine. This study has directly quantified the kinetics of agonist/G protein-coupled receptor interactions at the single-cell level, reflecting the physiological situation in which intracellular signaling proteins can exert major allosteric effects on agonist-receptor interactions. The association and dissociation rate constants at both A(1) and A(3) receptors, and therefore the affinity of the fluorescent adenosine derivative ABA-X-BY630 (structure appears in J Med Chem 50:782-793, 2007), were concentration-independent. The equilibrium dissociation constants of ABA-X-BY630 at A(1) and A(3) receptors were approximately 50 and 10 nM, respectively, suggesting that, even in live cells, low agonist concentrations predominantly detect high-affinity receptor states. At A(1) receptors, the dissociation of ABA-X-BY630 (30 nM) was significantly faster in the absence (k(off) = 1.95 +/- 0.09 min(-1)) compared with the presence of the allosteric enhancer (2-amino-4,5-dimethyl-3-thienyl)(3-(trifluoromethyl)phenyl)-methanone (PD81,723; 10 microM; k(off) = 0.80 +/- 0.03 min(-1)) and allosteric inhibitor 4-methoxy-N-(7-methyl-3-(2-pyridinyl)-1-isoquinolinyl)benzamide (VUF5455; 1 microM; k(off) = 1.48 +/- 0.16 min(-1)). In contrast, ABA-X-BY630 dissociation from A(3) receptors was significantly slower in the absence (k(off) = 0.78 +/- 0.18 min(-1)) than in the presence of the allosteric inhibitors VUF5455 (1 microM; k(off) = 3.15 +/- 0.12 min(-1)) and PD81,723 (10 microM; k(off) = 2.46 +/- 0.18 min(-1)). An allosteric mechanism of action has previously not been identified for PD81,723 at the A(3) receptor or VUF5455 at the A(1) receptor. Furthermore, the marked enhancement in fluorescent agonist dissociation by VUF5455 in living cells contrasts previous observations from broken cell preparations and emphasizes the need to study the allosteric regulation of agonist binding in living cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571079      PMCID: PMC2939483          DOI: 10.1124/mol.110.064493

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

1.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Authors:  Z G Gao; J E Van Muijlwijk-Koezen; A Chen; C E Müller; A P Ijzerman; K A Jacobson
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

Review 2.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

3.  The affinity of adenosine for the high- and low-affinity states of the human adenosine A1 receptor.

Authors:  F R Cohen; S Lazareno; N J Birdsall
Journal:  Eur J Pharmacol       Date:  1996-08-01       Impact factor: 4.432

Review 4.  Regulation of phosphoinositide-specific phospholipase C.

Authors:  S G Rhee
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

5.  Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.

Authors:  Y Cordeaux; S J Briddon; A E Megson; J McDonnell; J M Dickenson; S J Hill
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

Review 6.  Adenosine: trigger and mediator of cardioprotection.

Authors:  Michael V Cohen; James M Downey
Journal:  Basic Res Cardiol       Date:  2007-11-12       Impact factor: 17.165

7.  Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process.

Authors:  Brigitte Ilien; Nicole Glasser; Jean-Pierre Clamme; Pascal Didier; Etienne Piemont; Raja Chinnappan; Sandrine B Daval; Jean-Luc Galzi; Yves Mely
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

8.  The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.

Authors:  F R Cohen; S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 9.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

10.  Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.

Authors:  Yang Han; Irina S Moreira; Eneko Urizar; Harel Weinstein; Jonathan A Javitch
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

View more
  27 in total

Review 1.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.

Authors:  Dong Guo; Suzanne N Venhorst; Arnault Massink; Jacobus P D van Veldhoven; Georges Vauquelin; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 3.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

Review 4.  New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.

Authors:  Elizabeth A Vecchio; Jo-Anne Baltos; Anh T N Nguyen; Arthur Christopoulos; Paul J White; Lauren T May
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

Review 5.  Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands.

Authors:  Francisco Ciruela; Víctor Fernández-Dueñas; Kenneth A Jacobson
Journal:  Neuropharmacology       Date:  2015-04-16       Impact factor: 5.250

Review 6.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

Review 7.  Fluorescent ligands for adenosine receptors.

Authors:  Eszter Kozma; P Suresh Jayasekara; Lucia Squarcialupi; Silvia Paoletta; Stefano Moro; Stephanie Federico; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2012-11-05       Impact factor: 2.823

8.  Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay.

Authors:  Leigh A Stoddart; Andrea J Vernall; Jessica L Denman; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Chem Biol       Date:  2012-09-21

9.  Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.

Authors:  Jillian G Baker; Luke A Adams; Karolina Salchow; Shailesh N Mistry; Richard J Middleton; Stephen J Hill; Barrie Kellam
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

Review 10.  Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.

Authors:  Stephen J Hill; Lauren T May; Barrie Kellam; Jeanette Woolard
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.